CCDC78 Inhibitors

Compounds like ML-7 and Y-27632 target kinases involved in cytoskeletal dynamics and could thus interfere with any roles CCDC78 plays in cellular organization. PD98059 and U0126 specifically target the MEK/ERK pathway, a signaling cascade that can regulate a variety of cellular functions including those associated with CCDC78.

Further along these lines, SB203580, SP600125, and Staurosporine have the capacity to modulate stress-activated pathways and broad signaling cascades, which can indirectly impact CCDC78's activity. PI3K, a key regulator of intracellular signaling, can be inhibited by compounds like LY294002 and Wortmannin, thereby potentially altering the cellular context within which CCDC78 operates. Rapamycin, by inhibiting mTOR, can affect protein synthesis and cellular growth, pathways where CCDC78 might have a role. Additionally, Blebbistatin and Gö6983 offer more targeted approaches, the former by inhibiting myosin II ATPase and the latter by inhibiting protein kinase C. Both enzymes are integral to cell contractility and signaling, with possible connections to CCDC78's function.